Health TrialsbyHealthPanel

Refractory Medulloblastoma

3

Review clinical trials related to Refractory Medulloblastoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.

Participants needed: 24
Trial details
Phase: Phase 1Age: 3-22Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Oct 8, 2026Locations: 7
Eligibility criteria

Histologically confirmed diagnosis of a tumor that is known to express B7-H3 inc... [+25]

Patients with obstructive or symptomatic communicating hydrocephalus. [+3]

Read more
Status: Recruiting

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young adult patients with recurrent or refractory (R/R) medulloblastoma. Subjects with other non-medulloblastoma CNS embryonal tumors may enroll.

Participants needed: 18
Trial details
Phase: Phase 1Age: 1-30Biological sex: AllType: InterventionalSponsor: Stanford UniversityUpdated: Oct 9, 2026Locations: 1
Eligibility criteria

Diagnosis: Histologically confirmed diagnosis of medulloblastoma or other primar... [+29]

Any patient with metastatic disease OUTSIDE the CNS. [+12]

Read more
Status: Recruiting

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \</=39 years (Phase II) to test its safety and efficacy, respectively. Funding Source - FDA OOPD (grant number FD-R-0532-01)

Participants needed: 65
Trial details
Phase: Phase 1, Phase 2Age: 4-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Jul 20, 2026Locations: 4
Eligibility criteria

Screening Criteria [+32]

Read more